Drug Approval | December 12, 2025
Bristol Myers Squibb scores FDA priority review for Opdivo in advanced hodgkin lymphoma
The FDA aims to make a decision by April 8, 2026
The FDA aims to make a decision by April 8, 2026
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The new centre brings advanced corneal procedures pioneered in India
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Expands bioprocessing footprint across Asia
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The study met its primary endpoint and all 11 secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated
